<code id='BC2B1B0496'></code><style id='BC2B1B0496'></style>
    • <acronym id='BC2B1B0496'></acronym>
      <center id='BC2B1B0496'><center id='BC2B1B0496'><tfoot id='BC2B1B0496'></tfoot></center><abbr id='BC2B1B0496'><dir id='BC2B1B0496'><tfoot id='BC2B1B0496'></tfoot><noframes id='BC2B1B0496'>

    • <optgroup id='BC2B1B0496'><strike id='BC2B1B0496'><sup id='BC2B1B0496'></sup></strike><code id='BC2B1B0496'></code></optgroup>
        1. <b id='BC2B1B0496'><label id='BC2B1B0496'><select id='BC2B1B0496'><dt id='BC2B1B0496'><span id='BC2B1B0496'></span></dt></select></label></b><u id='BC2B1B0496'></u>
          <i id='BC2B1B0496'><strike id='BC2B1B0496'><tt id='BC2B1B0496'><pre id='BC2B1B0496'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:explore    - browse:56761
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus